Stem definition | Drug id | CAS RN |
---|---|---|
4755 | 746637-33-2 |
Molecule | Description |
---|---|
Synonyms:
|
Tilmanocept is a receptor-targeted radiopharmaceutical that is designed to rapidly transit lymphatic vessels; it biotargets, accumulates, and is retained in primary, key predictive, draining lymph nodes (sentinel lymphnodes). The drug substance, tilmanocept, specifically binds to mannose binding receptor proteins (CD206) that reside on the surface of macrophages and dendritic cells. Macrophages are present in high concentrations in lymph nodes.
|
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
March 13, 2013 | FDA | NAVIDEA BIOPHARMS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug ineffective | 245.65 | 167.69 | 80 | 47 | 1044685 | 62444210 |
None
None
None
Source | Code | Description |
---|---|---|
ATC | V09IA09 | VARIOUS DIAGNOSTIC RADIOPHARMACEUTICALS TUMOUR DETECTION Technetium (99mTc) compounds |
FDA MoA | N0000000205 | Radiopharmaceutical Activity |
FDA EPC | N0000177914 | Radioactive Diagnostic Agent |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Diagnostic aid | indication | 2949005 |
None
None
None
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
N/A | LYMPHOSEEK KIT | CARDINAL HEALTH 414 | N202207 | March 13, 2013 | RX | INJECTABLE | INJECTION | May 19, 2024 | NEW PATIENT POPULATION |
None
ID | Source |
---|---|
8IHI69PQTC | UNII |
4038731 | VANDF |
C3555537 | UMLSCUI |
CHEMBL2108726 | ChEMBL_ID |
DB09266 | DRUGBANK_ID |
C431884 | MESH_SUPPLEMENTAL_RECORD_UI |
1373391 | RXNORM |
203086 | MMSL |
207617 | MMSL |
1262984-82-6 | SECONDARY_CAS_RN |
None